TYMS and neutropenia: In the present study, we demonstrated that among BC patients who received CMF or FEC, those possessing the TS 2R/3R variant showed a significantly lower risk of severe toxicity (grade 3–4) for neutropenia and, when considering toxicity of any grade (G1–4), the same variant conferred a lower probability of developing oral mucositis.